Evidence map›Paper›PMID 19800570›Full record

ArticleCancer cell2009

Lymphotoxins: new targets for hepatocellular carcinoma.

Augusto Villanueva, Radoslav Savic, Josep M Llovet

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  2. Article
  3. Article
  4. Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2017
    Review
  5. Article
  6. Article
  7. Review
  8. Sorafenib: where do we go from here?Hepatology (Baltimore, Md.) · 2010
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Augusto VillanuevaHCC Translational Research Laboratory, Barcelona-Clinic Liver Cancer Group, Liver Unit. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clinic, BCN 08036, Barcelona, Spain.
Radoslav Savic
Josep M Llovet
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESIcahn School of Medicine at Mount Sinai · USInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

Integrative genomic analysis in hepatocellular carcinomaR01DK076986 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LLOVET, JOSEP M · 2007 to 2011
$1.3M
NIDDK NIH HHS 1R01DK076986-01NIDDK NIH HHS R01 DK076986
6 · The paper itself

Abstract

In this issue of Cancer Cell, Haybaeck et al. unravel the role of lymphotoxin pathway in the development of hepatocellular carcinoma (HCC). Aberrant activation of this cascade in mice livers recapitulates the stages of fibrosis and inflammation that precedes human liver cancer, providing a novel family of potential therapeutic targets.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, HepatocellularCell Transformation, ViralCytokinesGene Expression Regulation, NeoplasticHepatitis B, ChronicHepatitis C, ChronicHepatocytesHumansLiverLiver NeoplasmsLymphocytesLymphotoxin-alphaLymphotoxin-betaLymphotoxin beta ReceptorBiomarkers, TumorCytokinesLymphotoxin-alphaLymphotoxin-betaLymphotoxin beta Receptor

Identifiers

PMID19800570
PMCPMC3677157
OpenAlexW2016414929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.